Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bismuth tribromophenate is an organobismuth compound with the molecular formula C18H6BiBr9O3 and a molecular weight of approximately 1198 g/mol[2][5][6]. It appears as a bright yellow powder that is slightly soluble in water and stable below 120°C[6]. Bismuth tribromophenate is primarily used as a topical antiseptic and disinfectant agent in wound care dressings—most notably under the brand name Xeroform—as well as for burns, lacerations, abrasions, skin graft sites, and hemorrhoids[2][4][5][9]. Its mechanism of action involves antimicrobial activity through the release of bismuth ions that disrupt microbial organelles and cellular functions; this leads to bacterial cell death and inhibition of pathogens such as Staphylococcus aureus (including MRSA), Escherichia coli, Pseudomonas aeruginosa, Candida albicans among others[5][7]. The compound also promotes wound healing by maintaining a moist environment when formulated with petrolatum[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bismuth tribromophenate.